Details for Liver fibrosis: Direct antifibrotic agents and targeted therapies

PropertyValue
Name:Liver fibrosis: Direct antifibrotic agents and targeted therapies
Description:

Liver fibrosis and in particular cirrhosis are the major causes of morbidity and mortality of patients with chronic liver disease. Their prevention or reversal have become major endpoints in clinical trials with novel liver specific drugs. Remarkable progress has been made with therapies that efficiently address the cause of the underlying liver disease, as in chronic hepatitis B and C. Highly effective antiviral therapy can prevent progression or even induce reversal in the majority of patients, but such treatment remains elusive for the majority of liver patients with advanced alcoholic or nonalcoholic steatohepatitis, genetic or autoimmune liver diseases. Moreover, drugs that would speed up fibrosis reversal are needed for patients with cirrhosis, since even with effective causal therapy reversal is slow or the disease may further progress. Therefore, highly efficient and specific antifibrotic agents are needed that can address advanced fibrosis, i.e., the detrimental downstream result of all chronic liver diseases. This review discusses targeted antifibrotic therapies that address molecules and mechanisms that are central to fibrogenesis or fibrolysis, including strategies that allow targeting of activated hepatic stellate cells and myofibroblasts and other fibrogenic effector cells. Focus is on collagen synthesis, integrins and cells and mechanisms specific including specific downregulation of TGFbeta signaling, major extracellular matrix (ECM) components, ECM-crosslinking, and ECM-receptors such as integrins and discoidin domain receptors, ECM-crosslinking and methods for targeted delivery of small interfering RNA, antisense oligonucleotides and small molecules to increase potency and reduce side effects. With an increased understanding of the biology of the ECM and liver fibrosis and an improved preclinical validation, the translation of these approaches to the clinic is currently ongoing. Application to patients with liver fibrosis and a personalized treatment is tightly linked to the development of non-invasive biomarkers of fibrosis, fibrogenesis and fibrolysis.

Authors:Schuppan, D. et al
Journal Title:Matrix Biology
Journal Year:2018
Volume / Issue No.:68-69
Digital Object Identifier:http://dx.doi.org/10.1016/j.matbio.2018.04.006
Filename:NoDoc1546270941.htm
Filesize: 256 Bytes
Filetype:htm (Mime Type: text/html)
Creator:ixscient
Created On: 12/31/2018 15:42
Viewers:Everybody
Maintained by:ixscient
Hits:171 Hits
Last updated on: 12/31/2018 15:48
Homepage:
CRC Checksum:
MD5 Checksum: